论文部分内容阅读
目的探讨膀胱癌(BC)患者血清血管内皮生长因子(VEGF)水平与BC分期、分级的关系及手术前后变化的临床意义。方法采用酶联免疫吸附试验(ELISA)对62例BC患者术前、术后1个月、术后出现复发(19例)或远处转移(2例)者、50例正常人血清中VEGF水平进行检测。结果BC组的血清VEGF水平(269·2±58·3)ng/L明显高于正常对照组(125·5±22·3)ng/L(P<0·01),并与肿瘤的分期、分级相关;其中浸润性癌T2-T3(275·7±41·2)ng/L组明显高于浅表性癌Tis-T1(214·6±32·4)ng/L组(P<0·01),浸润性癌T4(338·8±43·7)ng/L组明显高于T2-T3组(P<0·01),G3级VEGF水平(332·9±45·6)ng/L显著高于G1级(231·2±38·5)ng/L和G2级(252·6±45·3)ng/L,G1级和G2级之间差异无统计学意义。与术前相比,术后血清VEGF水平(142·4±31·8)ng/L明显下降(P<0·01),而术后复发及转移组血清VEGF水平(256·3±93·2)ng/L再次明显上升高于正常对照组(P<0·01)。结论VEGF表达与膀胱癌的临床分期及病理分级相关,血清VEGF水平可作为膀胱癌患者手术前后病情监测及判断复发的一个新瘤标。
Objective To investigate the relationship between the serum level of vascular endothelial growth factor (VEGF) and the stage and grade in patients with bladder cancer (BC) and their clinical significance before and after operation. Methods The serum levels of VEGF in 62 patients with BC were measured by enzyme-linked immunosorbent assay (ELISA) before surgery, one month after surgery, recurrence (19 cases) or distant metastasis (2 cases) Test. Results The serum level of VEGF in BC group (269 · 2 ± 58 · 3) ng / L was significantly higher than that in the control group (125 · 5 ± 22 · 3) ng / L (P <0.01) (275.7 ± 41.2) ng / L for invasive carcinoma was significantly higher than that of superficial carcinoma Tis-T1 (214.6 ± 32.4) ng / L (P < 0.01). The invasive cancer T3 (338.8 ± 43.7) ng / L group was significantly higher than the T2-T3 group (P <0.01), the G3 level of VEGF (332.9 ± 45.6) ng / L was significantly higher than that of G1 (231 · 2 ± 38 · 5) ng / L and G2 (252 · 6 ± 45 · 3) ng / L, with no significant difference between G1 and G2. Compared with preoperative, serum VEGF level (142.4 ± 31.8) ng / L decreased significantly (P <0.01), but postoperative recurrence and metastasis serum VEGF level (256.3 ± 93 · 2) ng / L again significantly higher than the normal control group (P <0.01). Conclusions VEGF expression is correlated with the clinical stage and pathological grade of bladder cancer. Serum VEGF level may be used as a new tumor marker for bladder cancer patients’ condition monitoring and recurrence before and after operation.